Multifluid Metabolomics Identifies Novel Biomarkers for Irritable Bowel Syndrome.

Background/Objectives : Irritable bowel syndrome (IBS) is a complex disorder affecting 10% of the global population, but the underlying mechanisms remain poorly understood. By integrating multifluid metabolomics, we aimed to identify metabolite markers of IBS in a large population-based cohort. Methods : We included individuals from TwinsUK with and without IBS, ascertained using the Rome III criteria, and analysed serum (232 cases, 1707 controls), urine (185 cases, 1341 controls), and stool (186 cases, 1284 controls) metabolites (Metabolon Inc.). Results : After adjusting for covariates, and multiple testing, 44 unique metabolites (25 novel) were associated with IBS, including lipids, amino acids, and xenobiotics. Androsterone sulphate, a sulfated steroid hormone precursor, was associated with lower odds of IBS in both urine (0.69 [95% confidence interval = 0.56-0.85], p = 2.34 × 10 ^-4 ) and serum (0.75 [0.63-0.90], p = 1.54 × 10 ^-3 . Moreover, suberate (C8-DC) was associated with higher odds of IBS in serum (1.36 [1.15-1.61]; p = 1.84 × 10 ^-4 ) and lower odds of IBS in stool (0.76 [0.63-0.91]; p = 2.30 × 10 ^-3 ). On the contrary, 32 metabolites appeared to be fluid-specific, including indole, 13-HODE + 9-HODE, pterin, bilirubin (E,Z or Z,Z), and urolithin. The remaining 10 metabolites were associated with IBS in one fluid with suggestive evidence ( p < 0.05) in another fluid. Finally, we identified androgenic signalling, dicarboxylates, haemoglobin, and porphyrin metabolism to be significantly over-represented in individuals with IBS compared to controls. Conclusions : Our results highlight the utility of a multi-fluid approach in IBS research, revealing distinct metabolic signatures across biofluids.